Pharmaceutical - Asia-Pacific, Boehringer Ingelheim

Filter

Popular Filters

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth

20-12-2013

The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds

06-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Gilead gains FDA priority review for hep C candidate sofosbuvir; new data on Boehringer's faldaprevir

10-06-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) revealed on Friday (June 7) that the US Food and Drug…

Anti-viralsAsia-PacificBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesNorth AmericaPharmaceuticalRegulationResearchsofosbuvir

Boehringer Ingelheim to build biopharma facility in China

07-06-2013

German family-owned drug major Boehringer Ingelheim has signed a strategic alliance agreement and contract…

Asia-PacificBiotechnologyBoehringer IngelheimFinancialPharmaceuticalProductionShanghai Zhangjiang Biotech

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

COMPANY SPOTLIGHT

Menarini

Back to top